1 Market Overview

1.1 Product Overview and Scope of Selective Cox-2 Inhibitors

1.2 Classification of Selective Cox-2 Inhibitors by Type

1.2.1 Overview: Global Selective Cox-2 Inhibitors Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Type in 2021

1.2.3 Meloxicam

1.2.4 Celecoxib

1.2.5 Etoricoxib

1.2.6 Imrecoxib

1.2.7 Etodolac

1.2.8 Parecoxib

1.2.9 Other

1.3 Global Selective Cox-2 Inhibitors Market by Application

1.3.1 Overview: Global Selective Cox-2 Inhibitors Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Rheumatoid Arthritis

1.3.3 Osteoarthritis

1.3.4 Spondylosis Chronica Ankylopoietica

1.3.5 Other

1.4 Global Selective Cox-2 Inhibitors Market Size & Forecast

1.5 Global Selective Cox-2 Inhibitors Market Size and Forecast by Region

1.5.1 Global Selective Cox-2 Inhibitors Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Selective Cox-2 Inhibitors Market Size by Region, (2017-2022)

1.5.3 North America Selective Cox-2 Inhibitors Market Size and Prospect (2017-2028)

1.5.4 Europe Selective Cox-2 Inhibitors Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Selective Cox-2 Inhibitors Market Size and Prospect (2017-2028)

1.5.6 South America Selective Cox-2 Inhibitors Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Selective Cox-2 Inhibitors Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Selective Cox-2 Inhibitors Market Drivers

1.6.2 Selective Cox-2 Inhibitors Market Restraints

1.6.3 Selective Cox-2 Inhibitors Trends Analysis

2 Company Profiles

2.1 Boehringer-Ingelheim

2.1.1 Boehringer-Ingelheim Details

2.1.2 Boehringer-Ingelheim Major Business

2.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Product and Solutions

2.1.4 Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Boehringer-Ingelheim Recent Developments and Future Plans

2.2 TerSera Therapeutics

2.2.1 TerSera Therapeutics Details

2.2.2 TerSera Therapeutics Major Business

2.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Product and Solutions

2.2.4 TerSera Therapeutics Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 TerSera Therapeutics Recent Developments and Future Plans

2.3 Iroko Pharmaceuticals

2.3.1 Iroko Pharmaceuticals Details

2.3.2 Iroko Pharmaceuticals Major Business

2.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions

2.3.4 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Iroko Pharmaceuticals Recent Developments and Future Plans

2.4 Apotex

2.4.1 Apotex Details

2.4.2 Apotex Major Business

2.4.3 Apotex Selective Cox-2 Inhibitors Product and Solutions

2.4.4 Apotex Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Apotex Recent Developments and Future Plans

2.5 Yung Shin Pharmaceutical

2.5.1 Yung Shin Pharmaceutical Details

2.5.2 Yung Shin Pharmaceutical Major Business

2.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions

2.5.4 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Yung Shin Pharmaceutical Recent Developments and Future Plans

2.6 Breckenridge Pharmaceutical

2.6.1 Breckenridge Pharmaceutical Details

2.6.2 Breckenridge Pharmaceutical Major Business

2.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions

2.6.4 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Breckenridge Pharmaceutical Recent Developments and Future Plans

2.7 Meda Pharmaceuticals

2.7.1 Meda Pharmaceuticals Details

2.7.2 Meda Pharmaceuticals Major Business

2.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions

2.7.4 Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Meda Pharmaceuticals Recent Developments and Future Plans

2.8 Cipla

2.8.1 Cipla Details

2.8.2 Cipla Major Business

2.8.3 Cipla Selective Cox-2 Inhibitors Product and Solutions

2.8.4 Cipla Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Cipla Recent Developments and Future Plans

2.9 Glenmark Pharmaceuticals

2.9.1 Glenmark Pharmaceuticals Details

2.9.2 Glenmark Pharmaceuticals Major Business

2.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions

2.9.4 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Glenmark Pharmaceuticals Recent Developments and Future Plans

2.10 Teva

2.10.1 Teva Details

2.10.2 Teva Major Business

2.10.3 Teva Selective Cox-2 Inhibitors Product and Solutions

2.10.4 Teva Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Teva Recent Developments and Future Plans

2.11 PuraCap Pharmaceutical

2.11.1 PuraCap Pharmaceutical Details

2.11.2 PuraCap Pharmaceutical Major Business

2.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions

2.11.4 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 PuraCap Pharmaceutical Recent Developments and Future Plans

2.12 Almirall Limited

2.12.1 Almirall Limited Details

2.12.2 Almirall Limited Major Business

2.12.3 Almirall Limited Selective Cox-2 Inhibitors Product and Solutions

2.12.4 Almirall Limited Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Almirall Limited Recent Developments and Future Plans

2.13 Lupin Pharmaceuticals

2.13.1 Lupin Pharmaceuticals Details

2.13.2 Lupin Pharmaceuticals Major Business

2.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions

2.13.4 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Lupin Pharmaceuticals Recent Developments and Future Plans

2.14 Aurobindo Pharma

2.14.1 Aurobindo Pharma Details

2.14.2 Aurobindo Pharma Major Business

2.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Product and Solutions

2.14.4 Aurobindo Pharma Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 Aurobindo Pharma Recent Developments and Future Plans

2.15 Pfizer

2.15.1 Pfizer Details

2.15.2 Pfizer Major Business

2.15.3 Pfizer Selective Cox-2 Inhibitors Product and Solutions

2.15.4 Pfizer Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15.5 Pfizer Recent Developments and Future Plans

2.16 Mylan

2.16.1 Mylan Details

2.16.2 Mylan Major Business

2.16.3 Mylan Selective Cox-2 Inhibitors Product and Solutions

2.16.4 Mylan Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.16.5 Mylan Recent Developments and Future Plans

2.17 Takeda

2.17.1 Takeda Details

2.17.2 Takeda Major Business

2.17.3 Takeda Selective Cox-2 Inhibitors Product and Solutions

2.17.4 Takeda Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.17.5 Takeda Recent Developments and Future Plans

2.18 Bayer

2.18.1 Bayer Details

2.18.2 Bayer Major Business

2.18.3 Bayer Selective Cox-2 Inhibitors Product and Solutions

2.18.4 Bayer Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.18.5 Bayer Recent Developments and Future Plans

2.19 Novacap

2.19.1 Novacap Details

2.19.2 Novacap Major Business

2.19.3 Novacap Selective Cox-2 Inhibitors Product and Solutions

2.19.4 Novacap Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.19.5 Novacap Recent Developments and Future Plans

2.20 Abbott

2.20.1 Abbott Details

2.20.2 Abbott Major Business

2.20.3 Abbott Selective Cox-2 Inhibitors Product and Solutions

2.20.4 Abbott Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.20.5 Abbott Recent Developments and Future Plans

2.21 Geri-Care

2.21.1 Geri-Care Details

2.21.2 Geri-Care Major Business

2.21.3 Geri-Care Selective Cox-2 Inhibitors Product and Solutions

2.21.4 Geri-Care Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.21.5 Geri-Care Recent Developments and Future Plans

2.22 Perrigo

2.22.1 Perrigo Details

2.22.2 Perrigo Major Business

2.22.3 Perrigo Selective Cox-2 Inhibitors Product and Solutions

2.22.4 Perrigo Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.22.5 Perrigo Recent Developments and Future Plans

2.23 Kopran

2.23.1 Kopran Details

2.23.2 Kopran Major Business

2.23.3 Kopran Selective Cox-2 Inhibitors Product and Solutions

2.23.4 Kopran Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.23.5 Kopran Recent Developments and Future Plans

2.24 Merck

2.24.1 Merck Details

2.24.2 Merck Major Business

2.24.3 Merck Selective Cox-2 Inhibitors Product and Solutions

2.24.4 Merck Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.24.5 Merck Recent Developments and Future Plans

2.25 Hengrui pharmaceutical

2.25.1 Hengrui pharmaceutical Details

2.25.2 Hengrui pharmaceutical Major Business

2.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Product and Solutions

2.25.4 Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.25.5 Hengrui pharmaceutical Recent Developments and Future Plans

2.26 Kelun Group

2.26.1 Kelun Group Details

2.26.2 Kelun Group Major Business

2.26.3 Kelun Group Selective Cox-2 Inhibitors Product and Solutions

2.26.4 Kelun Group Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.26.5 Kelun Group Recent Developments and Future Plans

2.27 Qilu Pharmaceutical

2.27.1 Qilu Pharmaceutical Details

2.27.2 Qilu Pharmaceutical Major Business

2.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions

2.27.4 Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.27.5 Qilu Pharmaceutical Recent Developments and Future Plans

2.28 Taro Pharmaceuticals 

2.28.1 Taro Pharmaceuticals  Details

2.28.2 Taro Pharmaceuticals  Major Business

2.28.3 Taro Pharmaceuticals  Selective Cox-2 Inhibitors Product and Solutions

2.28.4 Taro Pharmaceuticals  Selective Cox-2 Inhibitors Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.28.5 Taro Pharmaceuticals  Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Selective Cox-2 Inhibitors Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Selective Cox-2 Inhibitors Players Market Share in 2021

3.2.2 Top 10 Selective Cox-2 Inhibitors Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Selective Cox-2 Inhibitors Players Head Office, Products and Services Provided

3.4 Selective Cox-2 Inhibitors Mergers & Acquisitions

3.5 Selective Cox-2 Inhibitors New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Selective Cox-2 Inhibitors Revenue and Market Share by Type (2017-2022)

4.2 Global Selective Cox-2 Inhibitors Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Selective Cox-2 Inhibitors Revenue Market Share by Application (2017-2022)

5.2 Global Selective Cox-2 Inhibitors Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Selective Cox-2 Inhibitors Revenue by Type (2017-2028)

6.2 North America Selective Cox-2 Inhibitors Revenue by Application (2017-2028)

6.3 North America Selective Cox-2 Inhibitors Market Size by Country

6.3.1 North America Selective Cox-2 Inhibitors Revenue by Country (2017-2028)

6.3.2 United States Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

6.3.3 Canada Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

6.3.4 Mexico Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Selective Cox-2 Inhibitors Revenue by Type (2017-2028)

7.2 Europe Selective Cox-2 Inhibitors Revenue by Application (2017-2028)

7.3 Europe Selective Cox-2 Inhibitors Market Size by Country

7.3.1 Europe Selective Cox-2 Inhibitors Revenue by Country (2017-2028)

7.3.2 Germany Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

7.3.3 France Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

7.3.5 Russia Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

7.3.6 Italy Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Selective Cox-2 Inhibitors Revenue by Type (2017-2028)

8.2 Asia-Pacific Selective Cox-2 Inhibitors Revenue by Application (2017-2028)

8.3 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region

8.3.1 Asia-Pacific Selective Cox-2 Inhibitors Revenue by Region (2017-2028)

8.3.2 China Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

8.3.3 Japan Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

8.3.4 South Korea Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

8.3.5 India Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

8.3.7 Australia Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Selective Cox-2 Inhibitors Revenue by Type (2017-2028)

9.2 South America Selective Cox-2 Inhibitors Revenue by Application (2017-2028)

9.3 South America Selective Cox-2 Inhibitors Market Size by Country

9.3.1 South America Selective Cox-2 Inhibitors Revenue by Country (2017-2028)

9.3.2 Brazil Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

9.3.3 Argentina Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Selective Cox-2 Inhibitors Revenue by Type (2017-2028)

10.2 Middle East & Africa Selective Cox-2 Inhibitors Revenue by Application (2017-2028)

10.3 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country

10.3.1 Middle East & Africa Selective Cox-2 Inhibitors Revenue by Country (2017-2028)

10.3.2 Turkey Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

10.3.4 UAE Selective Cox-2 Inhibitors Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Selective Cox-2 Inhibitors Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Selective Cox-2 Inhibitors Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Selective Cox-2 Inhibitors Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Selective Cox-2 Inhibitors Revenue (USD Million) by Region (2017-2022)

Table 5. Global Selective Cox-2 Inhibitors Revenue Market Share by Region (2023-2028)

Table 6. Boehringer-Ingelheim Corporate Information, Head Office, and Major Competitors

Table 7. Boehringer-Ingelheim Major Business

Table 8. Boehringer-Ingelheim Selective Cox-2 Inhibitors Product and Solutions

Table 9. Boehringer-Ingelheim Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. TerSera Therapeutics Corporate Information, Head Office, and Major Competitors

Table 11. TerSera Therapeutics Major Business

Table 12. TerSera Therapeutics Selective Cox-2 Inhibitors Product and Solutions

Table 13. TerSera Therapeutics Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Iroko Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 15. Iroko Pharmaceuticals Major Business

Table 16. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions

Table 17. Iroko Pharmaceuticals Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Apotex Corporate Information, Head Office, and Major Competitors

Table 19. Apotex Major Business

Table 20. Apotex Selective Cox-2 Inhibitors Product and Solutions

Table 21. Apotex Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Yung Shin Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 23. Yung Shin Pharmaceutical Major Business

Table 24. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions

Table 25. Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Breckenridge Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 27. Breckenridge Pharmaceutical Major Business

Table 28. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions

Table 29. Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Meda Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 31. Meda Pharmaceuticals Major Business

Table 32. Meda Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions

Table 33. Meda Pharmaceuticals Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Cipla Corporate Information, Head Office, and Major Competitors

Table 35. Cipla Major Business

Table 36. Cipla Selective Cox-2 Inhibitors Product and Solutions

Table 37. Cipla Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Glenmark Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 39. Glenmark Pharmaceuticals Major Business

Table 40. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions

Table 41. Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Teva Corporate Information, Head Office, and Major Competitors

Table 43. Teva Major Business

Table 44. Teva Selective Cox-2 Inhibitors Product and Solutions

Table 45. Teva Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. PuraCap Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 47. PuraCap Pharmaceutical Major Business

Table 48. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions

Table 49. PuraCap Pharmaceutical Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Almirall Limited Corporate Information, Head Office, and Major Competitors

Table 51. Almirall Limited Major Business

Table 52. Almirall Limited Selective Cox-2 Inhibitors Product and Solutions

Table 53. Almirall Limited Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Lupin Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 55. Lupin Pharmaceuticals Major Business

Table 56. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product and Solutions

Table 57. Lupin Pharmaceuticals Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Aurobindo Pharma Corporate Information, Head Office, and Major Competitors

Table 59. Aurobindo Pharma Major Business

Table 60. Aurobindo Pharma Selective Cox-2 Inhibitors Product and Solutions

Table 61. Aurobindo Pharma Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Pfizer Corporate Information, Head Office, and Major Competitors

Table 63. Pfizer Major Business

Table 64. Pfizer Selective Cox-2 Inhibitors Product and Solutions

Table 65. Pfizer Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 66. Mylan Corporate Information, Head Office, and Major Competitors

Table 67. Mylan Major Business

Table 68. Mylan Selective Cox-2 Inhibitors Product and Solutions

Table 69. Mylan Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 70. Takeda Corporate Information, Head Office, and Major Competitors

Table 71. Takeda Major Business

Table 72. Takeda Selective Cox-2 Inhibitors Product and Solutions

Table 73. Takeda Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 74. Bayer Corporate Information, Head Office, and Major Competitors

Table 75. Bayer Major Business

Table 76. Bayer Selective Cox-2 Inhibitors Product and Solutions

Table 77. Bayer Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 78. Novacap Corporate Information, Head Office, and Major Competitors

Table 79. Novacap Major Business

Table 80. Novacap Selective Cox-2 Inhibitors Product and Solutions

Table 81. Novacap Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 82. Abbott Corporate Information, Head Office, and Major Competitors

Table 83. Abbott Major Business

Table 84. Abbott Selective Cox-2 Inhibitors Product and Solutions

Table 85. Abbott Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 86. Geri-Care Corporate Information, Head Office, and Major Competitors

Table 87. Geri-Care Major Business

Table 88. Geri-Care Selective Cox-2 Inhibitors Product and Solutions

Table 89. Geri-Care Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 90. Perrigo Corporate Information, Head Office, and Major Competitors

Table 91. Perrigo Major Business

Table 92. Perrigo Selective Cox-2 Inhibitors Product and Solutions

Table 93. Perrigo Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 94. Kopran Corporate Information, Head Office, and Major Competitors

Table 95. Kopran Major Business

Table 96. Kopran Selective Cox-2 Inhibitors Product and Solutions

Table 97. Kopran Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 98. Merck Corporate Information, Head Office, and Major Competitors

Table 99. Merck Major Business

Table 100. Merck Selective Cox-2 Inhibitors Product and Solutions

Table 101. Merck Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 102. Hengrui pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 103. Hengrui pharmaceutical Major Business

Table 104. Hengrui pharmaceutical Selective Cox-2 Inhibitors Product and Solutions

Table 105. Hengrui pharmaceutical Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 106. Kelun Group Corporate Information, Head Office, and Major Competitors

Table 107. Kelun Group Major Business

Table 108. Kelun Group Selective Cox-2 Inhibitors Product and Solutions

Table 109. Kelun Group Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 110. Qilu Pharmaceutical Corporate Information, Head Office, and Major Competitors

Table 111. Qilu Pharmaceutical Major Business

Table 112. Qilu Pharmaceutical Selective Cox-2 Inhibitors Product and Solutions

Table 113. Qilu Pharmaceutical Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 114. Taro Pharmaceuticals  Corporate Information, Head Office, and Major Competitors

Table 115. Taro Pharmaceuticals  Major Business

Table 116. Taro Pharmaceuticals  Selective Cox-2 Inhibitors Product and Solutions

Table 117. Taro Pharmaceuticals  Selective Cox-2 Inhibitors Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 118. Global Selective Cox-2 Inhibitors Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 119. Global Selective Cox-2 Inhibitors Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 120. Breakdown of Selective Cox-2 Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3)

Table 121. Selective Cox-2 Inhibitors Players Head Office, Products and Services Provided

Table 122. Selective Cox-2 Inhibitors Mergers & Acquisitions in the Past Five Years

Table 123. Selective Cox-2 Inhibitors New Entrants and Expansion Plans

Table 124. Global Selective Cox-2 Inhibitors Revenue (USD Million) by Type (2017-2022)

Table 125. Global Selective Cox-2 Inhibitors Revenue Share by Type (2017-2022)

Table 126. Global Selective Cox-2 Inhibitors Revenue Forecast by Type (2023-2028)

Table 127. Global Selective Cox-2 Inhibitors Revenue by Application (2017-2022)

Table 128. Global Selective Cox-2 Inhibitors Revenue Forecast by Application (2023-2028)

Table 129. North America Selective Cox-2 Inhibitors Revenue by Type (2017-2022) & (USD Million)

Table 130. North America Selective Cox-2 Inhibitors Revenue by Type (2023-2028) & (USD Million)

Table 131. North America Selective Cox-2 Inhibitors Revenue by Application (2017-2022) & (USD Million)

Table 132. North America Selective Cox-2 Inhibitors Revenue by Application (2023-2028) & (USD Million)

Table 133. North America Selective Cox-2 Inhibitors Revenue by Country (2017-2022) & (USD Million)

Table 134. North America Selective Cox-2 Inhibitors Revenue by Country (2023-2028) & (USD Million)

Table 135. Europe Selective Cox-2 Inhibitors Revenue by Type (2017-2022) & (USD Million)

Table 136. Europe Selective Cox-2 Inhibitors Revenue by Type (2023-2028) & (USD Million)

Table 137. Europe Selective Cox-2 Inhibitors Revenue by Application (2017-2022) & (USD Million)

Table 138. Europe Selective Cox-2 Inhibitors Revenue by Application (2023-2028) & (USD Million)

Table 139. Europe Selective Cox-2 Inhibitors Revenue by Country (2017-2022) & (USD Million)

Table 140. Europe Selective Cox-2 Inhibitors Revenue by Country (2023-2028) & (USD Million)

Table 141. Asia-Pacific Selective Cox-2 Inhibitors Revenue by Type (2017-2022) & (USD Million)

Table 142. Asia-Pacific Selective Cox-2 Inhibitors Revenue by Type (2023-2028) & (USD Million)

Table 143. Asia-Pacific Selective Cox-2 Inhibitors Revenue by Application (2017-2022) & (USD Million)

Table 144. Asia-Pacific Selective Cox-2 Inhibitors Revenue by Application (2023-2028) & (USD Million)

Table 145. Asia-Pacific Selective Cox-2 Inhibitors Revenue by Region (2017-2022) & (USD Million)

Table 146. Asia-Pacific Selective Cox-2 Inhibitors Revenue by Region (2023-2028) & (USD Million)

Table 147. South America Selective Cox-2 Inhibitors Revenue by Type (2017-2022) & (USD Million)

Table 148. South America Selective Cox-2 Inhibitors Revenue by Type (2023-2028) & (USD Million)

Table 149. South America Selective Cox-2 Inhibitors Revenue by Application (2017-2022) & (USD Million)

Table 150. South America Selective Cox-2 Inhibitors Revenue by Application (2023-2028) & (USD Million)

Table 151. South America Selective Cox-2 Inhibitors Revenue by Country (2017-2022) & (USD Million)

Table 152. South America Selective Cox-2 Inhibitors Revenue by Country (2023-2028) & (USD Million)

Table 153. Middle East & Africa Selective Cox-2 Inhibitors Revenue by Type (2017-2022) & (USD Million)

Table 154. Middle East & Africa Selective Cox-2 Inhibitors Revenue by Type (2023-2028) & (USD Million)

Table 155. Middle East & Africa Selective Cox-2 Inhibitors Revenue by Application (2017-2022) & (USD Million)

Table 156. Middle East & Africa Selective Cox-2 Inhibitors Revenue by Application (2023-2028) & (USD Million)

Table 157. Middle East & Africa Selective Cox-2 Inhibitors Revenue by Country (2017-2022) & (USD Million)

Table 158. Middle East & Africa Selective Cox-2 Inhibitors Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Selective Cox-2 Inhibitors Picture

Figure 2. Global Selective Cox-2 Inhibitors Revenue Market Share by Type in 2021

Figure 3. Meloxicam

Figure 4. Celecoxib

Figure 5. Etoricoxib

Figure 6. Imrecoxib

Figure 7. Etodolac

Figure 8. Parecoxib

Figure 9. Other

Figure 10. Selective Cox-2 Inhibitors Revenue Market Share by Application in 2021

Figure 11. Rheumatoid Arthritis Picture

Figure 12. Osteoarthritis Picture

Figure 13. Spondylosis Chronica Ankylopoietica Picture

Figure 14. Other Picture

Figure 15. Global Selective Cox-2 Inhibitors Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 16. Global Selective Cox-2 Inhibitors Revenue and Forecast (2017-2028) & (USD Million)

Figure 17. Global Selective Cox-2 Inhibitors Revenue Market Share by Region (2017-2028)

Figure 18. Global Selective Cox-2 Inhibitors Revenue Market Share by Region in 2021

Figure 19. North America Selective Cox-2 Inhibitors Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. Europe Selective Cox-2 Inhibitors Revenue (USD Million) and Growth Rate (2017-2028)

Figure 21. Asia-Pacific Selective Cox-2 Inhibitors Revenue (USD Million) and Growth Rate (2017-2028)

Figure 22. South America Selective Cox-2 Inhibitors Revenue (USD Million) and Growth Rate (2017-2028)

Figure 23. Middle East and Africa Selective Cox-2 Inhibitors Revenue (USD Million) and Growth Rate (2017-2028)

Figure 24. Selective Cox-2 Inhibitors Market Drivers

Figure 25. Selective Cox-2 Inhibitors Market Restraints

Figure 26. Selective Cox-2 Inhibitors Market Trends

Figure 27. Boehringer-Ingelheim Recent Developments and Future Plans

Figure 28. TerSera Therapeutics Recent Developments and Future Plans

Figure 29. Iroko Pharmaceuticals Recent Developments and Future Plans

Figure 30. Apotex Recent Developments and Future Plans

Figure 31. Yung Shin Pharmaceutical Recent Developments and Future Plans

Figure 32. Breckenridge Pharmaceutical Recent Developments and Future Plans

Figure 33. Meda Pharmaceuticals Recent Developments and Future Plans

Figure 34. Cipla Recent Developments and Future Plans

Figure 35. Glenmark Pharmaceuticals Recent Developments and Future Plans

Figure 36. Teva Recent Developments and Future Plans

Figure 37. PuraCap Pharmaceutical Recent Developments and Future Plans

Figure 38. Almirall Limited Recent Developments and Future Plans

Figure 39. Lupin Pharmaceuticals Recent Developments and Future Plans

Figure 40. Aurobindo Pharma Recent Developments and Future Plans

Figure 41. Pfizer Recent Developments and Future Plans

Figure 42. Mylan Recent Developments and Future Plans

Figure 43. Takeda Recent Developments and Future Plans

Figure 44. Bayer Recent Developments and Future Plans

Figure 45. Novacap Recent Developments and Future Plans

Figure 46. Abbott Recent Developments and Future Plans

Figure 47. Geri-Care Recent Developments and Future Plans

Figure 48. Perrigo Recent Developments and Future Plans

Figure 49. Kopran Recent Developments and Future Plans

Figure 50. Merck Recent Developments and Future Plans

Figure 51. Hengrui pharmaceutical Recent Developments and Future Plans

Figure 52. Kelun Group Recent Developments and Future Plans

Figure 53. Qilu Pharmaceutical Recent Developments and Future Plans

Figure 54. Taro Pharmaceuticals  Recent Developments and Future Plans

Figure 55. Global Selective Cox-2 Inhibitors Revenue Share by Players in 2021

Figure 56. Selective Cox-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 57. Global Top 3 Players Selective Cox-2 Inhibitors Revenue Market Share in 2021

Figure 58. Global Top 10 Players Selective Cox-2 Inhibitors Revenue Market Share in 2021

Figure 59. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 60. Global Selective Cox-2 Inhibitors Revenue Share by Type in 2021

Figure 61. Global Selective Cox-2 Inhibitors Market Share Forecast by Type (2023-2028)

Figure 62. Global Selective Cox-2 Inhibitors Revenue Share by Application in 2021

Figure 63. Global Selective Cox-2 Inhibitors Market Share Forecast by Application (2023-2028)

Figure 64. North America Selective Cox-2 Inhibitors Sales Market Share by Type (2017-2028)

Figure 65. North America Selective Cox-2 Inhibitors Sales Market Share by Application (2017-2028)

Figure 66. North America Selective Cox-2 Inhibitors Revenue Market Share by Country (2017-2028)

Figure 67. United States Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Canada Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Mexico Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Europe Selective Cox-2 Inhibitors Sales Market Share by Type (2017-2028)

Figure 71. Europe Selective Cox-2 Inhibitors Sales Market Share by Application (2017-2028)

Figure 72. Europe Selective Cox-2 Inhibitors Revenue Market Share by Country (2017-2028)

Figure 73. Germany Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. France Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. United Kingdom Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Russia Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. Italy Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 78. Asia-Pacific Selective Cox-2 Inhibitors Sales Market Share by Type (2017-2028)

Figure 79. Asia-Pacific Selective Cox-2 Inhibitors Sales Market Share by Application (2017-2028)

Figure 80. Asia-Pacific Selective Cox-2 Inhibitors Revenue Market Share by Region (2017-2028)

Figure 81. China Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 82. Japan Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 83. South Korea Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 84. India Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 85. Southeast Asia Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 86. Australia Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 87. South America Selective Cox-2 Inhibitors Sales Market Share by Type (2017-2028)

Figure 88. South America Selective Cox-2 Inhibitors Sales Market Share by Application (2017-2028)

Figure 89. South America Selective Cox-2 Inhibitors Revenue Market Share by Country (2017-2028)

Figure 90. Brazil Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 91. Argentina Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 92. Middle East and Africa Selective Cox-2 Inhibitors Sales Market Share by Type (2017-2028)

Figure 93. Middle East and Africa Selective Cox-2 Inhibitors Sales Market Share by Application (2017-2028)

Figure 94. Middle East and Africa Selective Cox-2 Inhibitors Revenue Market Share by Country (2017-2028)

Figure 95. Turkey Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 96. Saudi Arabia Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 97. UAE Selective Cox-2 Inhibitors Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 98. Methodology

Figure 99. Research Process and Data Source